New unique shot that has been shown to reduce high blood pressure for 6 months, researchers say
Patients receiving treatment have seen significant reductions in blood pressure measures.
According to centers for disease control and prevention (CDC), having high blood pressure, also known as hypertension , puts you in danger for both cardiac disease And a stroke: the two main causes of death in the United States in mind - and with almost half of Americans diagnosed with hypertension - researchers regularly seek more effective means of keeping the condition under control. Lifestyle changes can be essential to do it, but doctors Recommend drugs to treat high blood pressure. And now there is a new treatment, a blow called Zilebesiran, which seems to give impressive results after a single dose. Read the rest to find out more about the latest discoveries.
In relation: A whole new medication reverses obesity without real side effects, say the researchers .
Researchers estimated nearly 400 patients with high blood pressure.
The results of the phase 2 Kardia-1 trial of the Zilebesiran experimental drug was announced on Saturday at the scientific meeting of the American Heart Association (AHA) 2023 in Philadelphia. AE0FCC31AE342FD3A1346EBB1F342FCB
According to a press release summarize the results, Researchers estimated 394 patients with an average age of 57 years and an average systolic blood pressure of 142 mmHg. (According to the CDC, hypertension is defined as a systolic blood pressure greater than 130 mmHg.) A total of 377 patients were included in the analyzes.
Participants were randomly assigned to a placebo group or one of the four Zilebesiran treatment groups: 150, 300 or 600 milligrams once every six months, or 300 milligrams once every three months.
In relation: Common statins increase the risk of diabetes, discovers a new study .
Zilebesiran has shown promising results.
The researchers discovered only one zilebesiran plan was both safe and effective in lowering blood pressure in adults with light to moderate hypertension for six months.
Patients who received a single dose of Zilebesiran had, on average, more than 10 mmHg of reduction in systolic blood pressure 24 hours a day, compared to those who received a placebo. According to the Cleveland Clinic, 24 -hour ambulatory blood pressure monitoring is taken on a continuous base for 24 hours.
During the evaluation of patients during the three -month follow -up, those who received a dose of 300 or 600 milligrams of Zilebesiran had a lowered blood pressure of 15 mmHg or more on average. After six months, those who received zilebesiran "were much more likely" to undergo reductions of 20 mmh or more without having to take additional medication. Also at this stage, patients who received zilebesiran were more likely to obtain systolic blood pressure measures 24 hours a day of 130 mmHg or less.
"Our study shows that the quarterly or biannual doses of Zilebesiran can effectively and safely reduce blood pressure in patients with uncontrolled hypertension", the main author of the study George L. Bakris , MD, FAHA, professor of medicine and director of the complete hypertension center of the University of Chicago, said in the AHA press release.
He continued: "It is well known that reductions in systolic blood pressure greater than or equal to 5 mm Hg are linked to a reduction in cardiovascular risk. Via an infrequent dosage and, in turn, improve the results for people suffering from high blood pressure. "
In relation: This daily walking plan can be all the cardio you need, shows a new study .
Zilebesiran patients have experienced additional advantages and limited side effects.
In addition to these improvements and larger reductions in day and night blood pressure pressure, those who received Zilebesiran also underwent 90% reductions in serum angiotensinogen (AGT) rates. According to the press release, the AGT is a hormone which is mainly produced in the liver and plays a role in the regulation of blood pressure.
The researchers also noted low unwanted event rates linked to Zilebesiran, the most common side effect being reactions on the shooting injection site. Bakris added that researchers have observed no "clinically relevant change in kidney or hepatic function".
Four participants interrupted the use of Zilebesiran due to unworthy unwanted events ", noted the researchers, two of whom reported orthostatic hypotension (low blood pressure that occurs during the sitting position or sleeping), One with an elevation of blood pressure and one with an injection site reaction. No adverse reaction was reported in the placebo group.
Additional research is necessary.
There were certain limits to the study cited in the press release, in particular that only people with light to moderate hypertension were evaluated.
In addition, the results were limited to the period controlled by a six -month placebo, the researchers noting that more studies are necessary to combat security and the longer -term impacts.
In relation: For more information, register for our daily newsletter .
Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.
